Navigation Links
SomaGenics Announces Issue of Key Patent for Its sshRNA Technology and Receipt of Two New Small Business Innovation NIH Grants
Date:11/12/2012

SANTA CRUZ, Calif., Nov. 12, 2012 /PRNewswire/ -- SomaGenics, Inc., a biotechnology company specializing in RNA-based technologies, has been awarded US Patent No. 8,283,460 for key aspects of the company's sshRNA therapeutic platform.  sshRNAs are small synthetic stem-loop (or hairpin) RNAs that the company's researchers have shown to be highly potent in knocking down target RNAs through an RNA interference (RNAi) mechanism.  SomaGenics' lead therapeutic program targets hepatitis C, and a number of sshRNAs directed at the hepatitis C virus are covered by the new patent.  'This patent, following on the award of US Patent 7,902,351 in 2011, represents another significant milestone in securing comprehensive patent protection for our sshRNA technology," commented SomaGenics CEO Brian Johnston.

SomaGenics also announced the receipt of two Small Business Innovation Grants from the National Institutes of Health totaling $647,000.  One, from the National Institute of General Medical Sciences, is entitled Accelerating Wound Healing Using RNAi and aims to speed healing of the hard-to-heal wounds that can particularly plague diabetics.  Dr. Sumedha Jayasena, VP of Therapeutic Development at SomaGenics, is principal investigator.

A second grant, awarded by the National Cancer Institute, is entitled A Novel Method for Quantitation of Fragmented mRNAs.  Its goal is to develop a new approach to analyzing gene expression from formalin-fixed, paraffin-embedded (FFPE) tissue specimens. Large repositories of FFPE specimens, each with pathologist interpretation and clinical records, are available at many medical institutions.  The ability to determine gene expression profiles for each specimen could make these archives a rich resource for discovering mRNA biomarkers of disease. Although RT-qPCR is the preferred method for quantitative analysis of gene expression, its sensitivity and robustness are significantly reduced with FFPE samples due to the degradation of mRNAs that occurs during specimen preparation and storage. SomaGenics' mR-FQ RT-qPCR approach should overcome these problems because, unlike standard PCR methods, it is unaffected by fragmentation; indeed, it explicitly makes use of it. The principal investigator for this grant is Dr. Sergei Kazakov, VP of Discovery Research at SomaGenics.

The new awards bring SomaGenics' total grant funding to well over $18 million and allow the company to develop new applications for its technologies.

Contact:

Dr. Brian Johnston
CEO, SomaGenics, Inc.
www.somagenics.com
bjohnston@somagenics.com
831-426-7700 x12

This press release was issued through eReleases® Press Release Distribution. For more information, visit http://www.ereleases.com.


'/>"/>
SOURCE SomaGenics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. SomaGenics Reports Study on Mechanism of Action of Its Therapeutic Platform
2. Karyopharm Therapeutics Announces Oral Presentation at the American College of Rheumatology (ACR) on the use of Selective Inhibitors of Nuclear Export (SINE) CRM1 Antagonists in preclinical models of Systemic Lupus Erythematosus (SLE)
3. AstraZeneca Announces Top-line Phase III Results from Naloxegol Pivotal Trials In Patients With Opioid-Induced Constipation
4. China Cord Blood Corporation Announces Completion of Strategic Partnership with Cordlife Group Limited
5. Apexigen Announces Initiation of Clinical Trials By Its Partner, Simcere Pharmaceutical Group
6. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2012 Financial Results
7. Boston Childrens Hospital announces international genomics competition winner
8. Sangamo BioSciences Announces Presentation At The Lazard Capital Markets Healthcare Conference
9. OncoGenex Announces Completion Of Patient Enrollment In Custirsen Phase 3 "SYNERGY" Study
10. AMRI Announces Third Quarter 2012 Results
11. Egenix, Inc. Announces New Director
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... New York , April 29, 2016 /PRNewswire/ ... report published by Transparency Market Research "Separation Systems ... Size, Share, Growth, Trends, and Forecast 2015 - ... was valued at US$ 10,665.5 Mn in 2014 ... of 6.8% from 2015 to 2023 to reach ...
(Date:4/29/2016)... ... April 29, 2016 , ... Summit for Stem Cell has received ... of a patient-specific stem cell therapy for the treatment of Parkinson’s disease. The Summit ... Loring at The Scripps Research Institute in San Diego, CA. , The ...
(Date:4/29/2016)... April 29, 2016 Elekta is ... update to its industry-leading treatment planning software, is available ... Monaco version 5.11 provides significant performance ... calculation speeds up to four times faster than in ... the industry,s gold standard Monte Carlo ...
(Date:4/28/2016)... 2016 Q BioMed Inc. ... CEO  was featured in an article he wrote ... Fear To Tread: http://www.lifescienceleader.com/doc/accelerators-enter-when-vcs-fear-to-tread-0001 ... is an essential business journal for life science ... to Big Pharmas. Their content is designed to ...
Breaking Biology Technology:
(Date:4/28/2016)... Sweden , April 28, 2016 First ... M (139.9), up 966% compared with the first quarter of 2015 ... profit totaled SEK 589.1 M (loss: 18.8) and the operating margin ... 7.12 (loss: 0.32) Cash flow from operations was SEK ... The 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. ...
(Date:4/15/2016)... 2016  A new partnership announced today will ... decisions in a fraction of the time it ... high-value life insurance policies to consumers without requiring ... Force Diagnostics, rapid testing (A1C, Cotinine and HIV) ... pressure, weight, pulse, BMI, and activity data) available ...
(Date:3/31/2016)... March 31, 2016   ... or the "Company") LegacyXChange is excited to ... its soon to be launched online site for trading ... ) will also provide potential shareholders a sense ... technology to an industry that is notorious for fraud. ...
Breaking Biology News(10 mins):